[
  {
    "id": "page-6de1-c29f",
    "text": ""
  },
  {
    "id": "page-0ca8-448a",
    "text": "과학기술정보통신부 소관 비영리법인\r\r02\r\rVol. 13"
  },
  {
    "id": "page-15bb-ab61",
    "text": "미래의학연구재단 액셀러레이터 프로그램 혜택\r“도전과 성장이 상생하는 지속 가능한 미래”\r\r· 대한민국 연구자라면 누구나 자유롭게 참여할 수 있습니다.\r\r· 전문 보육 프로그램을 통해 산학연 간극을 좁히고 바이오 스타트업 분야를 창조적으로 변모시키겠습니다.\r· 혁신적인 오픈이노베이션을 활성화하여 건강한 창업생태계를 구축하겠습니다.\r\r· 재단 후원금 일부를 직접 투자하고 회수하는 비영리 공익적 목적의 수익구조로 미래성장동력 발굴에 기여하겠습니다.\r\r스타트업 선발\r\r전문 보육\r\r액셀러레이팅\r\r오픈이노베이션\r\r04\r10\r1. 미래의학연구재단 액셀러레이터가 지원한 창업 기업의 혜택\r\r14\r\r· 벤처기업인증 미래의학연구재단 액셀러레이터가 투자?지원하면 벤처인증유형21\r중 벤처투자유형에 해당되어\r창업기업은 벤처기업으로 자동적으로 인증되어 창업 기업에 꼭 필요한 다수의 우선권 혜택 제공\r\r· 보육 바이오 분야에 특화 한 창업 기업 전문 보육프로그램, 보육공간 및 창업 기업 맞춤형 솔루션 무료 제공\r\r63\r\r· 오픈이노베이션 재단 협력기관과 맞춤형 네트워크를 통해 스케일 업에 필요한 고도화 프로그램 제공\r· 투자 재단의 직접 투자, 데모데이, 투자유치를 위한 IR 컨설팅, 후속 투자 유치 등의 투자 연계\r\r89\r\r2. 벤처기업인증제도\r\r114\r\r일반 기업과 비교했을 때 기술성이나 성장성이 상대적으로 높은 기업을 세계적인 기업으로 육성하기 위한 목표로\r창업, 세제, 입지, 특허, 마케팅 등을 지원하는 제도이며 인증 유효기간은 3년이다.\r\r116\r\r3. 벤처기업인증시 창업 기업에 제공되는 혜택\r\r1. 세제혜택 창업 기간이 3년 이내 기업의 경우 5년간 법인세와 소득세 50% 감면, 재산세 50%,\r취득세 75% 감면 등 소득공제(조특법 ’18.1.1. 시행)\r\r2. 금융혜택 금융기관으로부터 보증한도 확대(일반기업 30억 정도이나 벤처기업 50억의 보증한도 확대)\r\r3. 기타혜택 코스닥 상장 시 등록심사 우대, 정부지원금 심사 시 한도 우대, 마케팅 광고비 70%감면 등?\r\r55"
  },
  {
    "id": "page-3721-80d5",
    "text": ""
  },
  {
    "id": "page-916d-a043",
    "text": ""
  },
  {
    "id": "page-12d9-cb0f",
    "text": "김효수 교수는 1978년 서울대학교의예과에 입학한 후, 1984년 의\r\r하며, 그 동안 Lancet, Cell Stem Cell, European Heart J, Circu-\r\r터 기초연구에 입문하여 30년에 이르는 생명과학자입니다. 서울\r\rCell Research, EMBO J 등 임팩트팩터가 10이상인 잡지에 출판\r\r사로서 첫발을 내디딘 40년 경력의 임상의사인 동시에, 1992년부\r대학교병원 의생명연구원 연구원장으로서, 임상의사인 동시에 기\r초연구를 함께 수행하고 있습니다.\r\r김효수 교수는 “심혈관·줄기세포·생물학” 분야에만 꾸준히 매진\r\r하여 독창적인 다수의 연구결과를 도출하였고, 이를 상용화하기 위\r\r해서 집중한 결과 실용화 성과도 도출하면서 과학입국의 꿈을 구현\r하고 있습니다. 26년전에 일본 동경대학 의학부에서 유학하면서\r당시 새로운 분야이었던 심혈관 분자생물학을 국내에 도입한 개척\r\r자로서, 18년전에는 유전자치료/줄기세포 연구의 메카였던 미국\r보스턴의 성-엘리자베스 병원의 심혈관 연구소에서 유전자/세포\r생물학 기초연구에 몰두하였습니다. 즉 임상의사로서는 유래가 드\r\r물게 4년 동안 기초실험을 직접 수행한 생물학자로서, translational research를 실현한 뚝심 있는 의학자입니다.\r\r26년간 “심혈관·줄기세포·생물학” 분야에만 매진하면서 거둔 연\r구의 업적은 줄기세포 생물학의 독창적인 기초연구 성과를 진료\r현장에 도입해 심근경색 치료법인 ‘매직셀’이라는 혁신의료기술\r\r을 확립했습니다. 또 세포생물학 연구를 바탕으로 심근 재생을 위\r한 세포유전자 치료법 및 대사질환·지방간 치료법 개발, 패혈증\r치료제 개발 등에서 괄목할만한 성과를 도출하였습니다. 연구실적\r\r에서도 그의 논문들의 피인용 회수 총합계가 4만3천여 회를 상회\r\r04\r\rlation, Cell Metabolism, J Am College Cardiology, Blood,\r한 논문의 수가 187여편에 달하며, H-INDEX가 98에 도달하고 있\r습니다.\r\r김효수 교수는 탁월한 연구 성과를 인정받아서 2008년도 1회 아\r\r산의학상 대상을 수여하였고, 2014년도에 분쉬의학상 본상을 수\r상하였으며, 수훈내용이 탁월한 연구성과로서는 처음으로 2016\r년 대통령 훈장인 근정 훈장을 수상하였습니다.\r\r김효수 교수는 줄기세포생물학과 분자생물학을 기반으로 개발한\r의학 및 생명과학 분야의 원천 기술의 실용화를 위하여 2007년 줄\r기세포 치료제 개발을 목표로 ‘세포치료사업단’을 10년간 성공적\r\r으로 운영한 이후에 ‘중증난치질환 극복을 위한 세포치료 실용화\r\r센터’를 이끌고 있으며, 동시에 ‘연구중심병원사업의 바이오 치료\r제 개발’ 육성유니트 지휘자로서 바이오산업의 활성화를 위한 기\r\r초/상용화 연구에 몰두하고 있습니다. 김교수는 이러한 경험을\r\r바탕으로 2016년에 과학기술정보통신부 소관 비영리법인인 재단\r법인 미래의학연구 재단을 설립하였습니다.\r\r재단을 통해 대한민국 첨단 바이오 헬스 분야에 건강한 연구생태계\r를 조성하고, 연구자 중심 창업지원, 산학연병간 오픈이노베이션\r\r활성화를 통하여 대한민국 미래성장 동력 발굴에 이바지하고자 합\r니다."
  },
  {
    "id": "page-5f07-067c",
    "text": "05"
  },
  {
    "id": "page-4174-060a",
    "text": "06"
  },
  {
    "id": "page-b8cf-964e",
    "text": "3차 특허 생명과학 분야의 비영리 재단 주도 투자와 후원사를 매칭하는 오픈이노베이션 기반 창업 보육 성장\r시스템 및 방법(출원일 : 2022년 9월 19일)\r\r07"
  },
  {
    "id": "page-467f-3f70",
    "text": "(총40개기관협약완료, 협약확대중)\r\r08"
  },
  {
    "id": "page-5970-33b3",
    "text": "09"
  },
  {
    "id": "page-4f88-5df1",
    "text": "10"
  },
  {
    "id": "page-946e-9be4",
    "text": "11"
  },
  {
    "id": "page-de79-0528",
    "text": "12"
  },
  {
    "id": "page-aa02-5e9c",
    "text": "13"
  },
  {
    "id": "page-8bd5-46e8",
    "text": "14"
  },
  {
    "id": "page-76ce-9c9f",
    "text": "이승규\r\r? 한국바이오협회 상임부회장\r\r? 국가신약개발재단투자심의위원/이사\r\r김명정\r\r? (사)한국의료기기산업협회 상근부회장\r\r조욱제\r\r? (주)유한양행 대표이사\r\r? 과학기술정보통신부 ‘R&D투자혁신자문단’ 자문위원\r\r? 코스닥시장 기업심사위원회 심의위원단 위원\r\r김대중\r\r? 한국다이이찌산쿄(주) 대표이사 사장\r\r박경우\r\r? 이학 의학 박사, 경영학 석사\r\r? 서울대학교병원 순환기내과 교수\r? 서울대학교병원 강남센터 원장\r\r이은주\r\r? 서울대병원 첨단세포유전자치료센터\r센터장\r? 서울대학교병원 교수\r\r? 서울대학교의과대학 겸임교수\r\r15"
  },
  {
    "id": "page-9b49-3228",
    "text": "박경우\r\r김규원\r\r? 고려대학교 법학전문대학원 초빙교수\r\r? 서울대학교 약학대학 교수\r\r? 변호사 한상대법률사무소 변호사\r\r? 분자생물학 박사\r\r? 제38대 대검찰청 검찰총장\r\r? 제53대 서울중앙지방검찰청 검사장\r? 2012년 청조근정훈장\r\r? 2011년 제18회 자랑스러운 보성인상 수상\r\r김영소\r\r백성희\r\r? 마콜커뮤니케이션 컨설팅 고문\r\r? 서울대학교 자연과학대학 생명과학부 교수\r\r? 농학 박사\r\r오구택\r\r? 수의학 박사\r\r? 이화여자대학교 자연과학대학\r생명과학과 교수\r16\r\r? 이학 박사\r\r? 후성유전코드 및 질환 연구단 단장\r\r윤문태\r\r? (주)씨엔알러서치 대표이사"
  },
  {
    "id": "page-ba0d-693a",
    "text": "정윤택\r\r조현재\r\r? 중앙대학교 제약산업학과 객원교수\r\r? 서울대학교병원 순환기내과 교수\r\r? 제약산업전략연구원 원장\r\r? 연세대학교 약학대학 제약산업학 겸임교수\r\r? 이학 의학 박사\r\r? 의생명연구원 중개의학연구소 연구\r실험부 부장\r\r최지현\r\r? 삼진제약(주) 부사장\r\r17"
  },
  {
    "id": "page-3220-0766",
    "text": "윤수정\r\r? 한국발명진흥회 지식재산평가센터\r기술평가 전문위원\r\r18"
  },
  {
    "id": "page-8fcc-1160",
    "text": "김태형\r\r? 범부처전주의료기기연구개발단 본부장\r\r변승규\r\r? 법무법인 세움 파트너변호사\r\r19"
  },
  {
    "id": "page-91ca-a882",
    "text": "유용환\r\r? 이연제약 대표이사\r\r최호선\r\r? 한국평가데이터(주) 차장\r\r20"
  },
  {
    "id": "page-cc62-9ff3",
    "text": ""
  },
  {
    "id": "page-4a04-52b4",
    "text": "22"
  },
  {
    "id": "page-3eb2-1711",
    "text": "23"
  },
  {
    "id": "page-3ee8-ca49",
    "text": "24"
  },
  {
    "id": "page-5505-d7bb",
    "text": "25"
  },
  {
    "id": "page-d91e-4c99",
    "text": "26"
  },
  {
    "id": "page-c7b5-0118",
    "text": "27"
  },
  {
    "id": "page-08d0-e309",
    "text": "28"
  },
  {
    "id": "page-11c0-8fa6",
    "text": "29"
  },
  {
    "id": "page-e01b-2191",
    "text": "30"
  },
  {
    "id": "page-85b5-b167",
    "text": "31"
  },
  {
    "id": "page-b9bd-0eca",
    "text": "32"
  },
  {
    "id": "page-4442-552e",
    "text": "33"
  },
  {
    "id": "page-06a3-c059",
    "text": "34"
  },
  {
    "id": "page-63b4-2340",
    "text": "Bio-Venture Competition 구두 발표자 및 시상결과\r발표자/소속\r김희승 대표이사\r드림팩 주식회사\r\r윤성준 대표\r\r발표 주제\r약물저항성 고형암의 복막암종증 치료를 위한 회전복강고압에어로졸항암화요법\r기존 면역 세포치료제의 효능 및 생산보관의 한계를 극복하고 신규 항원의 탑재\r\r시상결과\r1 등 최우수상\r\r상금 1000 만원\r2 등 우수상\r\r㈜포투가바이오\r\r효율이 높은 새로운 복합치료제 플랫폼 개발을 통한 면역항암제의 불용성을 극복\r\r상금 500 만원\r\r이인희 대표\r\rAI 기반 성형수술용 의료영상 분석 및 맞춤 보형물 디자인\r\r3 등 장려상\r\r주식회사 핏미\r\r서비스를 제공하는 가상성형 플랫폼, The FACE On\r\r상금 300 만원\r\r35"
  },
  {
    "id": "page-7ac1-c203",
    "text": "바이오벤처 창업과 기업가 정신\r\r배신규\r㈜엠디뮨 대표이사\r\r36"
  },
  {
    "id": "page-7a48-6627",
    "text": "창업과 비즈모델\r\r37"
  },
  {
    "id": "page-a7b5-a4f1",
    "text": "병원의 기술실용화를 위한 노력\r\r38"
  },
  {
    "id": "page-dd45-edcc",
    "text": "밸류업 제고를 위한 바이오 기술가치평가의 이해\r\r39"
  },
  {
    "id": "page-df4e-97ae",
    "text": "제약 · 바이오 분야 기술기업 가치평가\r\r40"
  },
  {
    "id": "page-39c1-3c76",
    "text": "Introduction of the core technology of THEDONEE\r\r41"
  },
  {
    "id": "page-e0ed-fffa",
    "text": "스타트업, 벤처기업이 주의해야 하는 법률 이슈\r\r42"
  },
  {
    "id": "page-babe-dc04",
    "text": "43"
  },
  {
    "id": "page-cefe-ccc1",
    "text": "2022년 11월 25일(금) 오전 10시~오후 3시 45분\r\r노보텔 앰배서더 서울 동대문 그랜드 볼룸\r\rAllocate Time\r\r10:00~10:10\r\rDuration\rof time\r\r10'\r\rMorning Session\r\r44\r\rAgenda\r\rSpeaker (Affiliation)\rHyo-Soo Kim, M.D., Ph.D.\r(Director, Strategic Center of CBT\r(Cell & Bio Therapy) for Heart, Diabetes,\r& Cancer/ Seoul National University\rHospital, KOREA)\r\rOpening Remarks\r\rPanel :\rHyo-Soo Kim, M.D., Ph.D. (Seoul National University Hospital, KOREA)\rYoo-Wook Kwon, Ph.D. (Seoul National University Hospital, KOREA)\rHyun-Duk Jang, Ph.D. (Seoul National University Hospital, KOREA)\r\r10:10~10:35\r\r20'/5'\r\rTrends and Prospects of the\rGlobal Pharmaceutical Bio Industry\r\rYun-Taek Jung, Ph.D., TTA\r(Pharmaceutical Strategy Institute,\rKOREA)\r\r10:35~11:00\r\r20'/5'\r\rIP(Intellectual Property) Financing for\rTechnology\rCommercialization\r\rKi-Young Ko, Technical Analyst\r(Korea Invention Promotion Association,\rKOREA)\r\r11:00~11:25\r\r20'/5'\r\rLocational Selection and Growth\rStrategies for Biotechnology Startups\r\rDon Lee, COO\r(Medisola, KOREA)\r\r11:25~11:50\r\r20'/5'\r\rAdipose Tissue Stem Cells are Key\rDeterminants of Fat-Depot Specificity\r\rJae-Bum Kim, Ph.D.\r(Seoul National University, KOREA)\r\r11:50~12:15\r\r20'/5'\r\rDevelopment of Antibody for\rInflammatory Diseases (NASH, IBD, CANCER)\rBased on Resistin/Cap1 Biology\r\rHyo-Soo Kim, M.D., Ph.D.\r(Seoul National University Hospital,\rKOREA)\r\r12:15~13:00\r\r45'\r\rLunch"
  },
  {
    "id": "page-eefd-b522",
    "text": "Allocate Time\r\rDuration\rof time\r\rAfternoon Session\r\rAgenda\r\rSpeaker (Affiliation)\r\rPanel :\rHyo-Soo Kim, M.D., Ph.D. (Seoul National University Hospital, KOREA)\rYoo-Wook Kwon, Ph.D. (Seoul National University Hospital, KOREA)\rHyun-Duk Jang, Ph.D. (Seoul National University Hospital, KOREA)\r\r13:00~13:25\r\r20'/5'\r\rHidden Champions: The Exemplary\rInnovators of the 21st Century\rHow to Be Successful in Globalia\r\rPil-Hwa Yoo, Professor Emeritus\r(Sungkyunkwan University, KOREA)\r\r13:25~13:50\r\r20'/5'\r\rMajor Points in Contracts and\rCompliance for the Global Healthcare Market\r\rSun Yi, esq., LL.M\r(Law Firm Ipyeong, KOREA)\r\r13:50~14:15\r\r20'/5'\r\rAnalysis of the Factors of Changes in\rBio-Investment Environment and\rCorporate Value in 2022\r(with A Focus on Cell Gene Therapy)\r\rTae-kyu Lee, CEO\r(Scale Up Partners Ltd, KOREA)\r\r14:15~14:30\r\r15'\r\r14:30~15:00\r\r30'\r\rSomatic Mosaicism, Clonal Hematopoiesis\rand Cardiometabolic Disease\r\rKenneth Walsh, Ph.D.\r(University of Virginia, USA)\r\r15:00~15:30\r\r30'\r\rSelf-renewal Activity of\rHematopoietic Stem Cells\r\rToshio Suda M.D., Ph.D.\r(Kumamoto University, JAPAN)\r\r15:30~15:35\r\r5'\r\r15:35~15:45\r\r10'\r\rCoffee Break\r\rQuestion & Answer\r\rClosing Remarks\r\rHyo-Soo Kim, M.D., Ph.D.\r(Director, Strategic Center of CBT\r(Cell & Bio Therapy) for Heart, Diabetes,\r& Cancer/ Seoul National University\rHospital, KOREA)\r\r45"
  },
  {
    "id": "page-b54a-cefa",
    "text": "Trends and Prospects of the Global Pharmaceutical Bio Industry\r\rYun-Taek Jung\rPh.D., TTA (Pharmaceutical Strategy Institute, KOREA)\r\rThis lecture examines trends in the Korea and Global pharmaceutical&bio industry market, policy, and technology, and illuminates the future prospects based on this. In particular, based on the statistics of drug approval\rby the FDA in the US from about 2006 to 2021, the success rate by clinical stage and disease, etc.\r\r46"
  },
  {
    "id": "page-3105-3d39",
    "text": "IP(Intellectual Property) Financing for\rTechnology Commercialization\rKi-Young Ko\rTechnical Analyst (Korea Invention Promotion Association, KOREA)\r\rIn the new normal era, intellectual property has become a source of national competitiveness. IP transaction\rconsultants are a group of experts covering all industries in the Republic of Korea, and buyers can easily use\r\rintellectual property transaction services anywhere in the nation. The IP Transfer O?ce of the Korea Invention\rPromotion Association transforms a company’s potential into de?nite success by providing a total solution for\r\rintellectual property brokerage and transactions. We go beyond simply linking technology with technology and\rtechnology with companies, creating the new future value of mutual growth by providing accurate, fast and\r\rexpandable intellectual property brokerage and transaction services to the right people and at the right places.\rWe subsidize the cost of commercializationrelated valuation, performance analysis, and business feasibility,\ralong with valuation for ?nancial linkage such as guarantees, collateral loans, and investments using registered\r\rpatents. Those funds can be utilized in IP ?nance, technology transactions, in-kind investments, technology\rcerti?cations and more, ?nancing commercialization for small businesses and stimulating the utilization of\rpatented technologies.\r\r47"
  },
  {
    "id": "page-7d64-51f1",
    "text": "Locational Selection and Growth Strategies for\rBiotechnology Startups\rDon Lee\rCOO (Medisola, KOREA)\r\rBiotechnology and healthcare have become major engines for national and urban competitiveness, being seen\r\ras key innovative technologies for future economic growth. Yet it is a knowledge-driven sector with high uncer-\r\rtainties and costs. Growing rapidly in recent years, Korean bio-health industry has been building itself an\recosystem to oversee entire cycle of the sector, from R&D to licensing, leading to a number of clusters.\r\rThe concept of a cluster, de?ned by the OECD, is “a network between companies with strong independence,\r\rorganizations linked to the production value chain that creates value-added”. Providing linkage between the\rentities involved, with geographic focus, and the same or similar area of industry, a cluster has been used as a\rmeans of innovation through exchanges and interactions.\r\rAs the industry continues to expand, a vast number of biotech startups emerged centering around the technologies from academia and carried towards public through KRX’s special listing track. However, in reviewing of\r\rbusiness and ?nancial performances, a new evaluation model to conduct a more in-depth and objective evaluation is being prepared, requiring emerging startups to adapt an agile growth strategy in connection to the\rindustry/government initiatives and for attraction of ?nancial investors. This session highlights the importance\rconsiderations behind geographic considerations and growth strategies for biotech startups in the current\rmarket trend.\r\r48"
  },
  {
    "id": "page-489f-c113",
    "text": "Adipose Tissue Stem Cells are Key\rDeterminants of Fat-Depot Speci?city\rJae-Bum Kim\rPh.D. (Seoul National University, KOREA)\r\rHahn Nahmgoong1,4, Yong Geun Jeon1,4, Eun Seo Park2,4, Yoon Ha Choi2, Sang Mun Han1, Jeu Park1, Yul Ji1,\r\rJee Hyung Sohn1, Ji Seul Han1, Ye Young Kim1, In Jae Hwang1, Yun Kyung Lee3, Jin Young Huh1, Sung Sik Choe1,\rTae Jung Oh3, Sung Hee Choi3, Jong Kyoung Kim2, and Jae Bum Kim1\r\r1 Center for Adipocyte Structure and Function, Institute of Molecular Biology and Genetics, Department of\rBiological Sciences, Seoul National University, Seoul, 08826, Republic of Korea\r2 Department of New Biology, DGIST, Daegu, 42988, Republic of Korea\r\r3 Internal Medicine, Seoul National University College of Medicine & Seoul National University Bundang Hospital, Seoul, 03080, Republic of Korea\r\rIn mammals, white adipose tissues are largely divided into visceral epididymal adipose tissue (EAT) and subcu-\r\rtaneous inguinal adipose tissue (IAT) with distinct metabolic properties. Although emerging evidence suggests\r\rthat subpopulations of adipose stem cells (ASCs) in EAT and IAT would be important to explain fat depot di?erences, ASCs of two fat depots have not been comparatively investigated. Using single-cell RNA-sequencing with\rlean and obese mice, adoptive transplantation, and lymph node dissection, we characterized heterogeneous\rASCs in two fat depots and examined the e?ects of intrinsic and tissue micro-environmental factors on distinct\r\rASC features. We demonstrated that ASC clusters in EAT and IAT would exhibit di?erent molecular features with\rthree adipogenic stages and these features appeared to be conserved in human ASCs. Transplantation experi-\r\rments with EAT and IAT ASCs into two fat depots revealed that intrinsic features of ASCs primarily determined\radipogenic potential. Collectively, our data broaden the understandings of ASCs with new insights into the\rorigin of white fat depot di?erences.\r\r49"
  },
  {
    "id": "page-5b0b-1446",
    "text": ""
  },
  {
    "id": "page-56c7-ff81",
    "text": ""
  },
  {
    "id": "page-6149-38a9",
    "text": "Hidden Champions: The Exemplary Innovators of\rthe 21st Century How to Be Successful in Globalia\rPil-Hwa Yoo\rProfessor Emeritus (Sungkyunkwan University, KOREA)\r\rWe are living and will continue to live in the globalized world called Globalia. Which factors determine corporate suceess in Globalia?\r\rSuccess Factor 1 is INNOVATION. The exemplary innovators are the so-called Hidden Champions. Their R&D\r\rspending, number of patents, and cost per patent are truly impressive. What are the drivers of their innovation\rand how their innovation process is di?erent from that of other companies?\r\rSuccess Factor 2 is digitization. It is a huge challenge for the Hidden Champions.\rSuceess Factor 3 is the manufacturing base. These three factors (innovation, digitization, manufacturing\rbase) are interrelated.\r\rSuccess Factor 4 is value-to-customers. What really matters in the market is the value as perceived by\rcustomers.\r\rSuceess Factor 5 is securing independence and the last factor is leadership.\rI am going to discuss all these six success factors in detail during my lecture.\r\r52"
  },
  {
    "id": "page-8524-35ab",
    "text": "Major Points in Contracts and\rCompliance for the Global Healthcare Market\rSun Yi\resq.,LL.M (Law Firm Ipyeong, KOREA)\r\rAs the development of new drugs and medical devices have matured, the biotech businesses approach the time\r\rto consider commercialization of the products. Since the healthcare industry is one of the most regulated ?elds,\r\rit is tightly controlled what and when the companies can do in marketing. This presentation will provide the\rcritical points of the main compliance and legal points which biotech companies shall understand as they enter\rinto the marketization stage in the global market.\r\rHealthcare companies can marketize their products only after their products have cleared the relevant registrations in the competent government agencies/departments. The companies tend to prepare marketing activi-\r\rties so that they can sell their products as soon as their o?cial registrations have completed. However, health-\r\rcare products can never be seen as if “being commercialized” before the registrations cleared, and the de?nition of the commercialization is much inclusive. In the meantime, funding HCOs (healthcare organizations such\ras hopitals and clinics) and HCPs (healthcare professionals) for research and developments can usually be\r\rallowed before the registration of the products. Communications and any ?nancial transactions with HCOs and\rHCPs are easy to be considered as marketing activities for prescriptions after the products are dully registered\rin the market.\r\rIt cannot be emphasized enough the importance for the companies to understand what and when they can do\r\rfor e?cient but compliant marketing activities. The main mandatory rules which becomes the criteria are FCPA\rand GDPR. It often, if not always, appears that contracts with global partners have long complicated anti-cor-\r\rruption and data protection clauses. These clauses mainly consist of FCPA and GDPR laws. The presentation\r\rwill help the biotech companies to understand what those mandatory rules are and why we all need to comply\rwith these rules, so that they can plan their marketing activities not only e?ciently but compliantly with the\rimportant rules.\r\r53"
  },
  {
    "id": "page-4c8e-cf38",
    "text": "Analysis of the Factors of Changes in Bio-Investment\rEnvironment and Corporate Value in 2022\r(with A Focus on Cell Gene Therapy)\rTae-kyu Lee\rCEO (Scale Up Partners Ltd, KOREA)\r\r1. Analysis of the investment environment in the healthcare sector over the past 5 years and prediction of future\rinvestment environment\r\r2. Current status of growth curves and market-led platforms by major bio R&D sectors\r3. Current status of venture capital investment by major R&D sectors at home and abroad\r4. Setting goals and ?nancing strategies for each stage of growth of a company from a capital market perspective\r5. Considerations and factors for the growth of a company in the valuation of a bio-company\r\r54"
  },
  {
    "id": "page-4829-d65d",
    "text": "Somatic Mosaicism, Clonal Hematopoiesis\rand Cardiometabolic Disease\rKenneth Walsh\rPh.D. (University of Virginia, USA)\r\rThe Walsh lab investigates how the age-related condition of “clonal hematopoiesis” functions as a causal risk\rfactor for cardio-metabolic diseases. Exome sequencing studies in humans have shown that aging is associated\rwith the appearance of somatic mutations in hematopoietic stem cells that provide a competitive growth\radvantage to the mutant cell and allow for its clonal expansion. These stem cells give rise to progeny leukocytes\rthat harbor the mutation, potentially contributing to functional consequences in the immune system. While\r\rclonal hematopoiesis had long been viewed as a benign feature of the aging process, recent studies have shown\rthat it is associated with mortality due in large part to elevated cardiometabolic disease risk. However, the\r\rdescriptive nature of epidemiological studies makes it di?cult to assess causality, directionality or mechanism.\rUsing murine genetic models, we have provided evidence for a causal connection between clonal hematopoie-\r\rsis and cardiometabolic disease. These systems have allowed us to understand aspects of the underlying mechanisms, and some of these mechanistic details have been validated in clinical studies. Related to this work, we\r\rhave initiated a new research direction to examine mosaic loss of the Y chromosome (mLOY) in blood. mLOY is\rthe most common post-zygotic mutation in humans (>40% of men by 70 years of age). Epidemiological studies\rhave associated this prevalent form of aneuploidy with all-cause mortality and multiple age-associated pathol-\r\rogies. Our studies have provided the ?rst mechanistic evidence in support of a causal link between mLOY and\rage-associated cardiovascular dysfunction. In toto, these studies indicate that assessing clonal hematopoiesis\r\rstatus may provide information about an individual’s responses to immuno-modulatory therapies, thereby\renabling personalized medicine approaches in the treatment of cardiometabolic disease.\r\r55"
  },
  {
    "id": "page-33fa-417c",
    "text": "Self-renewal Activity of Hematopoietic\rStem Cells\rToshio Suda\rM.D., Ph.D. (Kumamoto University, JAPAN)\r\rTissue stem cells are capable of self-renewal and multi-lineage di?erentiation. The fate of hematopoietic stem\r\rcells (HSCs) is determined by the intrinsic cell program and the extrinsic microenvironment (niche) e?ect.\r\rAlthough self-renewal is essential for maintaining HSCs, the mechanism of the process has not been well eluci-\r\rdated. We have previously delineated that oxidative stress (ROS) limits the self-renewal activity of HSCs and\r\rthat the metabolic state is quite di?erent between quiescent (self-renewing) HSCs and cycling HSCs. Especially,\rwe are now analysing the mitochondria metabolism in stem cells.\r\rVery recently, we have clari?ed that in the period of HSC formation, they show the predominant self-renewal\r\rcapacity more than di?erentiation capacity to mature cells by using in vivo genetic tracing (Nature, Sep.2022).\rIn this symposium, I will talk about stem cell development and metabolism, which aims to regeneration medi-\r\rcine. From now, it will be a time to dissect how these two seemingly opposite tasks; self-renew and di?erentiation are regulated in stem cells.\r\r56"
  },
  {
    "id": "page-4d9c-ad99",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r프로그램 연자 소개\r\r57"
  },
  {
    "id": "page-4cb3-f9dd",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r프로그램 연자 소개\r\r58"
  },
  {
    "id": "page-7310-cd6e",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r참여기업 소개\r\r59"
  },
  {
    "id": "page-e01a-179b",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r· 프로그램\r\r12월 22일\r\r12월 27일\r60"
  },
  {
    "id": "page-fd3c-16e5",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r· 우수이수자상 시상\r\r우수이수자상 (주)파인트코리아 성룡 대표이사\r\r이수자 (주)더도니 박민희 연구소장\r61"
  },
  {
    "id": "page-5410-d251",
    "text": "IV-5. 2022 제2기 바이오헬스경영학교\r\r이수자 엘리펀트 임창진 대표"
  },
  {
    "id": "page-2fc2-e517",
    "text": ""
  },
  {
    "id": "page-f33b-21c0",
    "text": "22.02.17 | 제14회 이사회\r\r64"
  },
  {
    "id": "page-ba4b-88a7",
    "text": "22.05.02 | 미래의학연구재단-디오메디칼 MOU 체결\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r65"
  },
  {
    "id": "page-a5eb-2172",
    "text": "22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r66\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼"
  },
  {
    "id": "page-bcfa-c0c3",
    "text": "22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r22.05.06 | 재단법인 미래의학연구재단 제6회 춘계포럼\r\r67"
  },
  {
    "id": "page-3430-a7df",
    "text": "22.07.13 | 미래의학연구재단-재생의료진흥재단 MOU 체결\r\r22.07.13 | 미래의학연구재단-엠디뮨 MOU 체결\r\r68"
  },
  {
    "id": "page-650f-4564",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r69"
  },
  {
    "id": "page-55ae-cd41",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r70\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022"
  },
  {
    "id": "page-e107-d9c2",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r71"
  },
  {
    "id": "page-bd46-401d",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r72"
  },
  {
    "id": "page-8102-0dbd",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r73"
  },
  {
    "id": "page-a0ea-a2ef",
    "text": "22.08.12 | The 3rd BCC in 2022\r\r22.08.12 | The 3rd BCC in 2022\r\r74"
  },
  {
    "id": "page-1825-0b61",
    "text": "22.09.23 | 제1회 미래의학생명과학 창업지원사업\r\r22.09.23 | 제1회 미래의학생명과학 창업지원사업\r\r22.09.23 | 제1회 미래의학생명과학 창업지원사업\r\r75"
  },
  {
    "id": "page-d7bc-b8d0",
    "text": "22.09.23 | 제1회 미래의학생명과학 창업지원사업\r\r22.11.14 | 제15회 이사회\r\r76"
  },
  {
    "id": "page-3053-2bf3",
    "text": "22.11.14 | 제15회 이사회\r\r22.11.14 | 제15회 이사회\r\r22.11.14 | 제15회 이사회\r\r77"
  },
  {
    "id": "page-fc04-ebd7",
    "text": "22.11.14 | 제15회 이사회\r\r22.11.14 | 제15회 이사회\r\r22.11.14 | 제15회 이사회\r\r22.11.14 | 제15회 이사회\r\r78"
  },
  {
    "id": "page-2b06-4d3e",
    "text": "22.11.14 | 제15회 이사회\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r79"
  },
  {
    "id": "page-bac2-63e3",
    "text": "22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r80\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼"
  },
  {
    "id": "page-a549-6407",
    "text": "22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r81"
  },
  {
    "id": "page-d741-8ed4",
    "text": "22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r22.11.25 | 재단법인 미래의학연구재단 제6회 국제포럼\r\r82"
  },
  {
    "id": "page-3c53-b533",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r83"
  },
  {
    "id": "page-a063-62b5",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r84\r\r22.12.27 | 바이오헬스경영학교 종강식"
  },
  {
    "id": "page-5098-c259",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r85"
  },
  {
    "id": "page-62af-c399",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r86\r\r22.12.27 | 바이오헬스경영학교 종강식"
  },
  {
    "id": "page-5939-15a7",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r87"
  },
  {
    "id": "page-d40c-7ce6",
    "text": "22.12.27 | 바이오헬스경영학교 종강식\r\r22.12.27 | 바이오헬스경영학교 종강식\r\r88"
  },
  {
    "id": "page-a0e6-9a15",
    "text": ""
  },
  {
    "id": "page-2cd0-1e30",
    "text": "90\r40"
  },
  {
    "id": "page-9f83-d703",
    "text": "91"
  },
  {
    "id": "page-5d54-90ae",
    "text": "92"
  },
  {
    "id": "page-7dec-b123",
    "text": "93"
  },
  {
    "id": "page-e898-f826",
    "text": "94"
  },
  {
    "id": "page-daad-c208",
    "text": "배신규 대표이사\r(주)엠디뮨\r\r1988.2\r1985.2\r\rKAIST 생물공학과 졸업 (이학석사)\r아주대학교 생물공학 졸업\r\r(주)엠디뮨 대표이사\r\rProfessional Experience\r2022~현재\r\r한국바이오의약품협회 이사\r\r2015~현재\r\r(주)엠디뮨 창업, 대표이사\r\r2020~현재\r2011~2014\r2005~2011\r1997~2004\r1989~1997\r\r엑소좀산업협의회 회장\r\r(주)카이노스메드 사업개발담당 부사장\r(주)케미존 공동창업 및 경영총괄\r\r한미열린기술투자 투자심사역/파트너\r(주)대상 중앙연구소 책임연구원\r\r김도균 연구소장\r\rJMI 경영전략연구소\r\rJMI 경영전략연구소 소장\r\r성균관대학교 융합의과학원 마케팅전략\r\r95"
  },
  {
    "id": "page-38c7-aedc",
    "text": "이사람 교수\r\r서울대학교병원\r\r2014\r\r서울대학교 공과대학 의용생체공학\r\r박사\r\r서울대학교병원 융합의학과 부교수\r\r서울대학교병원 의생명연구원 연구지원본부 담당교수\r서울대학교 의과대학 겸임부교수\r2020.7.16\r\r2019.10.24\r\rEstimation and Validation of Arterial Blood Pressure Using Photoplethsymogram\rMorphology Features in Conjunction with Pulse Arrival Time in Large Open Databases\rIEEE Journal of Biomedical and Health Informatics\r\rAnalysis of Pulse Arrival Time as an Indicator of Blood Pressure in a Large Surgical\r\rBiosignal Database: Recommendations for Developing Ubiquitous Blood Pressure\rMonitoring Methods\r\r2019.9.18\r2018.12.5\r2018.6.18\r\r2018.5.19\r2018.3.1\r\r2017.7.1\r\r96\r\rJ Clin Med\r\rCuffless and Continuous Blood Pressure Monitoring Using a Single Chest-Worn Device\rIEEE Access\r\rBidirectional Recurrent Auto-Encoder for Photoplethysmogram Denoising\rIEEE Journal of Biomedical and Health Informatics\r\rNovel blood pressure and pulse pressure estimation based on pulse transit time and\rstroke volume approximation\rBiomed Eng Online\r\rRecent advances in electrochemical non-enzymatic glucose sensors ? A review\rAnalytica Chimica Acta\r\rDisposable non-enzymatic blood glucose sensing strip based on nanoporous platinum\rparticles\r\rApplied Materials Today\r\rApplication of genetic algorithm for hemodialysis schedule optimization\rComputer Methods and Programs in Biomedicine"
  },
  {
    "id": "page-be35-cc77",
    "text": "이정희 대표이사\r\r(주)디지털사이언스\r\r2021\r2018\r\r연세대학교(미래) 전산학\r\r충북대학교 의생명과학경영융합학\r\r박사\r\r석사\r\r(주)디지털사이언스 대표이사\r1. Jang, Y.-J.; Kim, M.-S.; Lee, C.-H.; Choi, J.-H.; Lee, J.-H.; Lee, S.-H.; Sung, T.-E. A Novel Approach on\r\rDeep Learning-Based Decision Support System Applying Multiple Output LSTM-Autoencoder: Focusing on\r\rIdentifying Variations by PHSMs’ Effect over COVID-19 Pandemic. Int. J. Environ. Res. Public Health 2022,\r19, 6763.\r\r2. Kim, M.-S.; Lee, C.-H.; Choi, J.-H.; Jang, Y.-J.; Lee, J.-H.; Lee, J.; Sung, T.-E. A Study on Intelligent\r\rTechnology Valuation System: Introduction of KIBO Patent Appraisal System II. Sustainability 2021, 13,\r12666.\r\r3. 김민승, 장용주, 이찬호, 최지혜, 이정희, 안민호, & 성태응. (2021). 기술력 평가모형 및 평가지표에 대한 연구: 해양수\r산업 을 중심으로. 한국콘텐츠학회논문지, 21(10), 90-102.\r\r4. 김민승, 이재식, 오은식, 이찬호, 최지혜, 장용주, 이정희. & 성태응. (2021). 딥러닝 기반 지능형 기술가치평가에 관한 연\r구: 심층신경망 학습을 통한 정성평가 지표 예측 모형. 기술혁신학회지, 24(6), 1141-1162.\r\r5. 성태응, 김민승, 이찬호, 최지혜, 장용주, & 이정희. (2021). 딥러닝 기반의 기술가치평가와 평가변수 추정. 한국콘텐츠\r학회 논문지, 21(10), 48-58.\r\r6. Lee, J. H., Kang, J., Shim, W., Chung, H. S., & Sung, T. E. (2020). Pattern Detection Model Using a Deep\rLearning Algorithm for Power Data Analysis in Abnormal Conditions. Electronics, 9(7), 1140.\r\r7. Kim, M. S., Lee, J. H., Jang, Y. J., Lee, C. H., Choi, J. H., & Sung, T. E. (2020). Hybrid deep learning algorithm\r\rwith open innovation perspective: A prediction model of asthmatic occurrence. Sustainability, 12(15),\r6143.\r\r8. 최지혜, 김민승, 이찬호, 최정환, 이정희, & 성태응. (2020). Hybrid CNN-LSTM 알고리즘을 활용한 도시철도 내 피플\r카운팅 연구. 지능정보연구, 26(2), 131-145.\r\r9. Woo, J., Kim, E., Sung, T. E., Lee, J., Shin, K., & Lee, J. (2019). Developing an improved risk-adjusted net\r\rpresent value technology valuation model for the biopharmaceutical industry. Journal of Open Innovation:\rTechnology, Market, and Complexity, 5(3), 45.\r\r10. Lee, J. H., Kim, E. D., Jun, E. J., Yoo, H. S., & Lee, J. W. (2018). Analysis of trends and prospects regarding\rstents for human blood vessels. Biomaterials research, 22(1), 1-10.\r\r11. Lee, J. H., Sung, T. E., Kim, E., & Shin, K. (2018). Evaluating determinant priority of license fee in biotech\rindustry. Journal of Open Innovation: Technology, Market, and Complexity, 4(3), 30.\r\r12. Lee, J. H., Kim, E., Sung, T. E., & Shin, K. (2018). Factors affecting pricing in patent licensing contracts in\rthe biopharmaceutical industry. Sustainability, 10(9), 3143.\r\r13. Lee, J. H., Khee-Su, B., Lee, J. W., In, Y., Kwon, T., & Lee, W. (2016). Valuation method by regression\ranalysis on real royalty-related data by using multiple input descriptors in royalty negotiations in Life\rScience area- focused on anticancer therapies. Journal of Open Innovation: Technology, Market, and\rComplexity, 2(4), 21\r\r14. Lee, J. H., In, Y., Lee, L., & Lee, J. W. (2016). Valuations using royalty data in the life sciences area?\r\rfocused on anticancer and cardiovascular therapies. Journal of Open Innovation: Technology, Market, and\rComplexity, 2(1), 1..\r\r97"
  },
  {
    "id": "page-f7dc-7fc1",
    "text": "최호선 차장\r\r한국평가데이터(주)\r\r2008-2010\r2003-2008\r\rSNU, Seoul National University\r\rMS of Management of Technology\r\rKAIST, Korea Advanced Institute of Science and Technology\r\r한국평가데이터(주) 차장\r\rWorking Experience\rKorea Rating & Data, Tech. Value Business Dept. (2021-2022)\rKorea Enterprise Data, AI & Contens Dept. (2018-2020)\r\rKorea Enterprise Data, Public Service Business Dept. (2015-2017)\rHyundai Motors Group, R&D Planning Team (2013-2014)\r\rHyundai Motors Group(Rotem), Facility Development Team (2010-2012)\r\rPublications\rBIO-IP ISSUE PAPER, VOL.04(2022, Presidential Council on Intellectual Property)\r\r박민희 연구소장\r(주)더도니\r\r2008.03~2014.02\r2004.03~2008.02\r(주)더도니 연구소장\r\r98\r\r이화여자대학교 화학나노과학과\r인제대학교 나노공학부\r\r공학사\r\r이학박사\r\rBS of Mechanical Engineering"
  },
  {
    "id": "page-7fa9-1fe0",
    "text": "1. JY Sim, HJ Lee, B, Jeong*, and MH Park*, Poly (Ethylene glycol)-poly (l-alanine)/hyaluronic acid complex\r\ras a 3d platform for understanding cancer cell migration in the tumor microenvironment, Polymers, 2021,\r13, 1042\r\r2. S Jeong, S Kim, Y Choi, HN Jung, K Lee*, and MH Park*, Development of Glycerol-Rose Bengal-Polydocanol\r(GRP) foam for enhanced sclerosis of a cyst for cystic disease, Plos one, 2021, 16, e0244635\r\r3. J Woo, H Seo, Y Na, S Choi, S Kim, Wi Choi, MH Park, and D Sung*, Facile synthesis and coating of\r\raqueous antifouling polymers for inhibiting pathogenic bacterial adhesion on medical devices, Progress\rin Organic Coatings, 2020, 147, 105772\r\r4. Y Choi, MH Park*, and K Lee*, Injectable thermoresponsive hydrogel/nanofiber hybrid scaffolds inducing\r\rhuman adipose-derived stem cell chemotaxis, Journal of Industrial and Engineering Chemistry, 2020, 82, 89\r5. Y Choi, MH Park*, and K Lee*Tissue Engineering Strategies for Intervertebral Disc Treatment using\rfunctional Polymers, Polymers, 2019, 11, 872\r\r6. H Kim, C Bae, Y Kook, W Koh, K Lee*, and MH Park*, Mesenchymal stem cell 3D encapsulation technologies\rfor biomimetic microenvironment in tissue regeneration, Stem Cell Research & Therapy, 2019, 10:51\r\r7. MH Park, R Subbiah, MJ Kwon, WJ Kim, SH Kim, K Park*, and K Lee*, The three dimensional cues-\r\rintegrated- biomaterial potentiates differentiation of human mesenchymal stem cells, Carbohydrate\rPolymers, 2018, 202, 488\r\r8. S Kim, BH Shin, C Yang S Jeong, JH Shim, MH Park, YB Choy, CY Heo*, and K Lee*, Development of\r\rPoly(HEMA- Am) Polymer Hydrogel Filler for Soft Tissue Reconstruction by Facile Polymerization, Polymers,\r2018, 10, 772\r\r9. C Yang, S Jeong, S Ku, K Lee*, and MH Park*, Use of gasotransmitters for the controlled release of\r\rpolymer- based nitric oxide carriers in medical applications, Journal of Controlled Release, 2018, 279, 157\r10. AF Tikum, YJ Jeon, JH Lee, MH Park, IY Bae, SH Kim, HJ Lee, and J Kim*, Cytotoxic and anticancer\r\rproperties of new ruthenium polypyridyl complexes with different lipophilicities, Journal of inorganic\rbiochemistry, 2018, 180, 204\r\r11. YM Kook, H Kim, S Kim, K Lee, CY Heo, MH Park, and WG Koh*, Promotion of Vascular Morphogenesis\r\rof Endothelial Cells Co-cultured with Human Adipose-derived Mesenchymal Stem Cells using\rPolycaprolactone/ Gelatin Nanofibrous Scaffolds, Nanomaterials, 2018, 8, 117\r\r12. A Bein, W Shin, S Jalili-Firoozinezhad, MH Park, A Sontheimer-Phelps, A Tovaglieri, A Chalkiadaki, HJ\r\rKim*, and KE Ingber*, Microfluidic Organ-on-a-Chip models of Human Intestine, Cellular and molecular\rgastroenterology and hepatology, 2018, 5, 659\r\r변승규 파트너 변호사\r법무법인 세움\r\r2012\r\rSeoul National University School of Law\r\rJuris Doctor\r\r법무법인 세움 파트너 변호사\r\rPublications : (Recent 5 Years) *Denotes Corresponding Authorship\rICLG Guide to: Private Equity 2018, Korea Chapter (4th Edition, Global Legal Group), co-authorship\r\r99"
  },
  {
    "id": "page-64c9-e34c",
    "text": "Yun-Taek Jung CEO\r\rPh.D., TTA (Pharmaceutical Strategy Institute, KOREA)\r\r2011 Year : Ph.D. Science and Technology Policy & Management, Korea University Graduate School, Dept. of\rScience and Technology Policy & Management Studies, Seoul, Republic of Korea\rCEO\r1. Yun-Taek Jung, Jin-Young Jo, Hun-Che Cho, Kwan-Young Chang, Sung-Hyun Hong, Young-Hyun Choi:\r\rA Discussion on the on Value Chain-based Policies and Regulations, for the Globalization in the Korean\rPharmaceutical Industry. KFDC, Vol.14, No.2, 0-14, 2019\r\r2. Jung Yun-Taek, A theory and study on the LCM(Life cycle management) and evergreening according to\rthe cases of patent litigation in the Korean pharmaceutical industry, Journal of Technology Innovation,\rVol.20,No.2, pp 135~1609, 2012\r\r3. Jung Yun-Taek, Patent strategy and market competition in the pharmaceutical field, The Korean\rJournal of Health Economics and Policy, Vol.18, No.1, pp 109~136, 2012\r\r4. Jung Yun-Taek, A Research on the Evergreening Patent Strategy and FTA in the Pharmaceuticals Field,\rThe Journal of Intellectual Property Vol.6 No.2, June 2011, pp 147-189\r\r5. Jung Yun-Taek, Effectiveness of FTA and Development in the Pharmaceutical industry, The Journal of\rIntellectual Property policy, Vol.6, March 2011, pp 44-51\r\rDon Lee COO\r\rMedisola, KOREA\r\r2015\r2012\r\rM.S. in Biotechnology\r\rUniversity University of Pennsylvania\r\rB.S. in Chemistry / Economics\r\rNew York University\r\rCOO\r\rWorking Experience\rMedisola, Chief Operating Officer\r\rKB Investment, Life Science & Health Investment Group, Senior Investment Manager\rSCM Lifescience, Business Development Manager\rPBG Healthcare Consulting, Consultant/Manager\r\rNew York Eye and Ear Infirmary of Mount Sinai, Clinical Researcher\r\rOther Positions Held\rKorea Health Industry Development Institute, Technology Startup Scout\r\rCouncil for Advanced Regenerative Medicine, International Cooperation Committee, Member\r100"
  },
  {
    "id": "page-754f-8826",
    "text": "Jae-Bum Kim Ph.D.\r\rSeoul National University, KOREA\r\r1991 ~ 1996\r\rPh.D.\r\r1984 ~ 1988\r\rB.S\r\r1988 ~ 1990\r\rM.A\r\rDept. of Microbiology & Molecular Genetics, Harvard University, Boston, USA\r\rCell & Molecular Biology, Seoul National University, Seoul, Korea\r\rDept. of Zoology, Seoul National University, Seoul, Korea\r\rProfessor\rJ. Park, D. H. Lee, S. Ham, J. Oh, J. Noh, Y. K. Lee, Y. J. Park, G. Lee, S. M. Han, J. S. Han, Y. Y. Kim, Y. G. Jeon,\rH. Nahmgoong, K. C. Shin, S. M. Kim, S. H. Choi, C. Lee, J. Park, T. Y. Roh, S. Kim, and J. B. Kim*. Targeted\rerasing of DNA methylation drives adipogenic reprogramming. Nat. Metab. 2022 Jul; 4:918-931.\r\rJ. S. Han, Y. G. Jeon, M. Oh, G. Lee, H. Nahmgoong, S. M. Han, Y. Y. Kim, K. C. Shin, J. Kim, K. Jo, S. S. Choe,\r\rE. J. Park, S. Kim, and J. B. Kim*. Adipocyte HIF2alpha functions as a thermostat via PKA C regulation in\rbeige adipo- cytes. Nat. Commun. 2022 Jun; 13:3268.\r\rG. Lee, Y. Y. Kim, H. Jang, J. S. Han, H. Nahmgoong, Y. J. Park, S. M. Han, C. Cho, S. Lim, J. Noh, W. K. Oh,\r\rC. Lee, S. Kim, and J. B. Kim*. SREBP1c-PARP1 axis tunes anti-senescence activity of adipocytes and\rameliorates metabolic imbalance in obesity. Cell Metab. 2022 May; 34:702-718. (This paper is introduced\ras ‘research highlights’ in Nat. Cell Biol. 24:601 [2022])\r\rH. Nahmgoong, Y. G. Jeon, E. S. Park, Y. H. Choi, S. M. Han, J. Park, Y. Ji, J. H. Sohn, J. S. Han, Y. Y. Kim, I.\rJ. Hwang, Y. K. Lee, J. Y. Huh, S. S. Choe, T. J. Oh, S. H. Choi, J. K. Kim, and J. B. Kim*. Distinct properties\r\rof adipose stem cell subpopulations determine fat depot-specific characteristics. Cell Metab. 2022 Mar;\r\r34:458-472. (This study is highlighted on the cover figure. This paper is highlighted in Nat. Rev. Endocrinol.\r18:133 [2022])\r\rY. J. Park, S. Lee, S. Lim, H. Nahmgoong, Y. Ji, J. Y. Huh, A. A. Alfadda, S. Kim, and J. B. Kim*. Dnmt1\r\rmaintains metabolic fitness of adipocytes through acting as an epigenetic safeguard of mitochondria\rdynamics. Proc. Natl. Acad. Sci. 2021 Mar; 118(11):e2021073118.\r\r101"
  },
  {
    "id": "page-d563-ed4b",
    "text": "Hyo-Soo Kim M.D., Ph.D.\r\rSeoul National University Hospital, KOREA\r\rMar. 1987 - Aug. 1994\r\rPostgraduate School, Seoul National University (Ph.D. in Medical Science)\r\rMar. 1980 - Feb. 1984\r\rSeoul National University College of Medicine (M.D.)\r\rMar. 1985 - Feb. 1987\r\rPostgraduate School, Seoul National University (Master of Medical Science)\r\rMar. 1978 - Feb. 1980 Premedical Course, College of Liberal Arts & Science, Seoul National University\rPresident, Biomedical Research Institute.\r\rProfessor, Department of Internal Medicine, Seoul National University College of Medicine\r\rDirector, Strategic Center of CBT (Cell & Bio Therapy) for Hear, Diabetes, & Caner (sponsored by MOHW)\rDirector, Biotherapy Unit, Program of Research-Driven Hospital (sponsored by MOHW)\rPresident, Korean Society of Circulation\rFellow, American Heart Association\r\rFellow, American College of Cardiology\r1. Jeehoon Kang, Kyung Woo Park, Huijin Lee, Doyeon Hwang, Han-Mo Yang, Seung-Woon Rha, Jang-Whan\rBae, Nam Ho Lee, Seung-Ho Hur, Jung-Kyu Han, Eun-Seok Shin, Bon-Kwon Koo, Hyo-Soo Kim, Aspirin vs.\r\rClopidogrel for Chronic Maintenance Monotherapy after Percutaneous Coronary Intervention: the HOSTEXAM Extended Study, Circulation 2022 (in press)\r\r2. Yoo-Wook Kwon, Cheong-Whan Chae, Hwan Lee, Dongsub Shin, Hyerin Yoo, Choon-Soo Lee, Younghyun\rLee, Ki Moon Seong, Hyo-Soo Kim, A subset of macrophages and monocytes in the mouse bone marrow\rexpress atypical chemokine receptor 1, Cell Stem Cell . 2022 Jul 7;29(7):1016-1017\r\r3. Han-Mo Yang; Joonoh Kim; Hyun-Duk Jang; Dasom Shin; Ju-Young Kim; Jihye You; Hyun-Chae Lee;\r\rSahmin Lee; Hyo-Soo Kim, Resistin Impairs Mitochondrial Homeostasis via Cyclase-associated Protein\r1-mediated Fission, Leading to Obesity-induced Metabolic Diseases, Metabolism 2022 (in press)\r\r4. Jeehoon Kang, Bon-Kwon Koo, Kyung Woo Park, Eun-Seok Shin, Hyo-Soo Kim, Aspirin versus clopidogrel\rafter percutaneous coronary intervention - Authors’ reply, Lancet . 2021 Nov 6;398(10312):1685-1686.\r\r5. Jin-Woo Lee, Jin Hur, Yoo-Wook Kwon, Cheong-Whan Chae, Jae-Il Choi, Injoo Hwang, Ji-Yeon Yun, Jin-A\r\rKang, Young-Eun Choi, Young Hyun Kim, Sang Eun Lee, Cheol Lee, Dong Hyun Jo, Heeyoung Seok, Byong\rSeung Cho, Sung Hee Baek, Hyo-Soo Kim, KAI1(CD82) is a key molecule to control angiogenesis and\rswitch angiogenic milieu to quiescent state, Journal of hematology & oncology 2021 Sep 16;14(1):148.\r\r6. Bon-Kwon Koo, Jeehoon Kang, Kyung Woo Park, Tae-Min Rhee, Han-Mo Yang, Ki-Bum Won, SeungWoon Rha, Jang-Whan Bae, Nam Ho Lee, Seung-Ho Hur, Junghan Yoon, Tae-Ho Park, Bum Soo Kim, Sang\rWook Lim, Yoon Haeng Cho, Dong Woon Jeon, Sang-Hyun Kim, Jung-Kyu Han, Eun-Seok Shin, Hyo-Soo\rKim, Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary\r\rintervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre\rtrial, Lancet. 2021 Jun 26;397(10293):2487-2496.\r\r7. Jung-Kyu Han, Youngchul Shin, Min-Hwan Sohn, Saet-Byeol Choi, Dasom Shin, Youngrang You, JongYeon Shin, Jeong-Sun Seo, Hyo-Soo Kim, Direct conversion of adult human fibroblasts into functional\rendothelial cells using defined factors, Biomaterials, 2021 May;272:120781 (Oline)\r\r8. Hyo-Soo Kim, Jeehoon Kang , Doyeon Hwang , Jung-Kyu Han , Han-Mo Yang , Hyun-Jae Kang, Bon-Kwon\rKoo , Seok Yeon Kim, Keun-Ho Park , Seung-Woon Rha , Won-Yong Shin , Hong-Seok Lim , Kyungil Park ,\r\rKyung Woo Park, Durable Polymer Versus Biodegradable Polymer Drug-Eluting Stents After Percutaneous\rCoronary Intervention in Patients with Acute Coronary Syndrome: The HOST-REDUCE-POLYTECH-ACS\rTrial, Circulation. 2021 Mar 16;143(11):1081-1091.\r102"
  },
  {
    "id": "page-e177-1ef6",
    "text": "9. Jin-Woo Lee, Choon-Soo Lee, Yong-Rim Ryu, Jaewon Lee, HyunJu Son, Hyun-Jai Cho, Hyo-Soo Kim,\r\rLysophosphatidic Acid Receptor 4 Is Transiently Expressed during Cardiac Differentiation and Critical for\rRepair of the Damaged Heart, Mol Ther. 2021 Mar 3;29(3):1151-1163\r\r10. Injoo Hwang, Eun Ju Lee, Hyomin Park, Dodam Moon, Jong Nam Park, Keun Cheon Kim, Areum Cha\r\r, Hyunji Yun, Jaewon Lee, Hwan-Woo Park, Mi-Sook Chang, Hyo-Soo Kim, Endothelin-1 enhances the\rregenerative capability of human bone marrow-derived mesenchymal stem cells in a sciatic nerve injury\rmouse model, Biomaterials 275 (2021) 120980\r\r11. Jeehoon Kang, Jun Pil Yun, You-Jeong Ki, Hak Seung Lee, Jung-Kyu Han, Han-Mo Yang, Kyung Woo\rPark, Hyun-Jae Kang, Bon-Kwon Koo, Hyo-Soo Kim, A New Hemodynamic Index Predicting Paravalvular\rRegurgitation After TAVR: Dicrotic AR Index, JACC: Cardiovascular Interventions Volume 13, Issue 22, 23\rNovember 2020, Pages 2711-2713\r\r12. Hyo-Soo Kim, Jeehoon Kang, Doyeon Hwang, Jung-Kyu Han, Han-Mo Yang, Hyun-Jae Kang, Bon-Kwon\rKoo, Jay Young Rhew, Kook-Jin Chun, Young-Hyo Lim, Jung Min Bong, Jang-Whan Bae, Bong Ki Lee, Kyung\rWoo Park, HOST-REDUCE-POLYTECH-ACS investigators Prasugrel-based de-escalation of dual antiplatelet\r\rtherapy after per- cutaneous coronary intervention in patients with acute coronary syndrome (HOST-\r\rREDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial, Lancet. 2020 Oct\r10;396(10257):1079-1089.\r\r13. Eun Ju Lee, Injoo Hwang, Ji Yeon Lee, Jong Nam Park, Keun Cheon Kim, Irene Kim, Dodam Moon,\rHyomin Park, Seo-Yeon Lee, Hong Sug Kim, Dae Won Jun, Sung-Hye Park, Hyo-Soo Kim, Hepatic stellate\r\rcell-specific knockout of transcriptional intermediary factor 1γ aggravates liver fibrosis, J Exp Med 2020\rJun 1;217(6):e20190402\r\r14. Han-Mo Yang, Ju-Young Kim, Hyun-Jai Cho, Joo-Eun Lee, Sooryeonhwa Jin, Jin Hur, Yoo-Wook Kwon,\rMoon- Woo Seong, Eue-Keun Choi, Hae-Young Lee, Hyun-Seob Lee, Mika Jeon, Joonoh Kim, Jaeseok\rYang, Seil Oh, Kyung- Suk Suh, Sung-Soo Yoon, Ki-Bong Kim, Byung-Hee Oh, Young-Bae Park, Hyo-Soo\r\rKim, NFATc1+CD31+CD45- circulating multipotent stem cells derived from human endocardium and their\rtherapeutic potential, Biomaterials. 2020 Feb;232:119674.\r\r15. Seo-Yeon Lee, Jimin Yang, Jung Hwa Park, Hwa Kyoung Shin, Woo Jean Kim, Su-Yeon Kim, Eun Ju Lee,\r\rInjoo Hwang, Choon-Soo Lee, Jaewon Lee, Hyo-Soo Kim, The MicroRNA-92a/Sp1/MyoD Axis Regulates\r\rHypoxic Stim- ulation of Myogenic Lineage Differentiation in Mouse Embryonic Stem Cells,Mol Ther. 2020\rJan 8;28(1):142-156\r\r16. Hyun-Duk Jang, Sang Eun Lee, Jimin Yang, Hyun-Chae Lee, Dasom Shin, Hwan Lee, Jaewon Lee,\rSooryeonhwa Jin, Soungchan Kim, Seung Ji Lee, Jihye You, Hyun-Woo Park, Ky-Youb Nam, Sang-Hak Lee,\rSahng Wook Park, Jin- Soo Kim, Sang-Yeob Kim, Yoo-Wook Kwon, Soo Heon Kwak, Han-Mo Yang, Hyo-Soo\r\rKim, Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and\ris required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/\rkexin type-9, Eur Heart J. 2020 Jan 7;41(2):239- 252.\r\r17. Young-Chan Kim, Sang Eun Lee, Somi K. Kim, Hyun-Duk Jang, Injoo Hwang, Sooryeonhwa Jin, EunByeol Hong, Kyoung-Soon Jang & Hyo-Soo Kim, Toll-like receptor mediated inflammation requires FASNdependent MYD88 palmitoylation, Nature Chemical Biology 2019 Sep;15(9):907-916.\r\r18. Choon-Soo Lee, Hyun-Jai Cho, Jin-Woo Lee, Jaewon Lee, Yoo-Wook Kwon, Taekwon Son, Hanseul\rPark, Jongpil Kim, Hyo-Soo Kim, Identification of Latrophilin-2 as a Novel Cell-Surface Marker for the\rCardiomyogenic Lineage and Its Functional Significance in Heart Development, Circulation. 2019 Jun\r18;139(25):2910-2912.\r\r19. Joo Myung Lee, Gilwoo Choi, Bon-Kwon Koo, Doyeon Hwang, Jonghanne Park, Jinlong Zhang, KyungJin Kim, Yaliang Tong, Hyun Jin Kim, Leo Grady, Joon-Hyung Doh, Chang-Wook Nam, Eun-Seok Shin,\r\rYoung-Seok Cho, Su-Yeon Choi, Eun Ju Chun, Jin-Ho Choi, Bjarne L Nørgaard, Evald H Christiansen, Koen\rNiemen, Hiromasa Otake, Martin Penicka, Bernard de Bruyne, Takashi Kubo, Takashi Akasaka, Jagat\rNarula, Pamela S Douglas, Charles A Taylor, Hyo-Soo Kim, Identification of high-risk plaques destined to\rcause acute coronary syndrome using coronary computedtomographicangiographyandcomputationalflui\rddynamics, JACC:Cardiovascular Imaging 2019 Jun;12(6):1032-1043.\r\r103"
  },
  {
    "id": "page-936e-7b5c",
    "text": "20. Tae-Min Rhee, Kyung Woo Park, Hyo-Soo Kim, Reply: Duration of Dual-Antiplatelet Therapy After\rLeft Main Stenting: Progressive Steps Towards the Correct Answer, JACC Cardiovasc Interv. 2019 Apr\r8;12(7):690-691.\r\r21. Tae-Min Rhee, Kyung Woo Park , Chi-Hoon Kim, Jeehoon Kang, Jung-Kyu Han , Han-Mo Yang, Hyun-Jae\rKang, Bon-Kwon Koo, Hyo-Soo Kim, Dual Antiplatelet Therapy Duration Determines Outcome After 2- But\rNot 1-Stent Strategy in Left Main Bifurcation Percutaneous Coronary Intervention, JACC Cardiovasc Interv.\r2018 Dec 24;11(24):2453-2463.\r\r22. Tae-Min Rhee, Joo Myung Lee, Eun-Seok Shin, Doyeon Hwang, Jonghanne Park, Ki-Hyun Jeon, Hack-\r\rLyoung Kim, Han-Mo Yang, Jung-Kyu Han, Kyung Woo Park, Joo-Yong Hahn, Bon-Kwon Koo, Sang-Hyun\rKim, Hyo-Soo Kim, Impact of optimized procedure-related factors in drug-eluting balloon angioplasty for\rtreatment of in-stent restenosis, JACC: Cardiovascular Interventions 2018 May 28;11(10):969-978.\r\r23. Hyo-Soo Kim, Tae-Min Rhee, Farewell to Drug-Eluting Balloons for In-Stent Restonsis?: Appropriate\r\rTechnique of Drug-Eluting Balloons Implantation Matters, JACC Cardiovasc Interv. 2018 May 28;11(10):992994.\r\r24. Eun Ju Lee, Injoo Hwang, Ji Yeon Lee, Jong Nam Park, Keun Cheon Kim, Gi-Hwan Kim, Chang-Mo Kang,\rIrene Kim, Seo-Yeon Lee, Hyo-Soo Kim, Hepatocyte Growth Factor Improves the Therapeutic Efficacy of\rHuman Bone Marrow Mesenchymal Stem Cells via RAD51, Mol Ther. 2018 Mar 7;26(3):845-859.\r\rPil-Hwa Yoo Professor Emeritus\r\rSungkyunkwan University, KOREA\r\r1986\r\rDoctor of Business Administration\r\rHarvard University\r\rProfessor Emeritus at SKK Graduate School of Business of Sunkyunkwan University\r2022\r\rWhat is Profit?\r\r2017\r\rWhat the Victorious Study?\r\r2021\r\r104\r\rThe Great Losers"
  },
  {
    "id": "page-6acb-2eb4",
    "text": "Sun Yi esq.,LL.M\r\rLaw Firm Ipyeong, KOREA\r\r2016 ~\r\rLL.M. in International Commercial Arbitration\r\rPepperdine University School of Law, Straus\r\r2009 ~ 2011\r\rMaster in Law Degree\r\rWonkwang University\r\r1998 ~ 2003\r\rB.A.s in Philosophy and Political Science\r\r2004 ~ 2006\r\rM.A. in International Studies\r\rInstitute of Dispute Resolution\rYonsei University\r\rSung Kyun Kwan University\r\rPartner attorney\r\rWork Experience\r2022. 4 ~ current\r\rLaw Firm Ipyeong, Partner attorney-at-law\r\r2019. 1 ~ 2020. 7\r\rSeegene Inc., In-house Counsel\r\r2020. 7 ~ 2022. 4\r\r2017. 9 ~ 2018. 12\r2015. 9 ~ 2016. 5\r2013 ~ 2015\r2010. 1 ~ 2010. 3\r2006. 3 ~ 2007. 4\r\rTeva-Handok Inc., Ltd., General Counsel and Compliance and Ethics Officer\rHDX Corporation, In-house Counsel\r\rLee, Hong, Degerman, Kang & Waimey (Law firm), Law Clerk (Korean Attorney) in the dispute\rresolutions team\r\rResearch Assistant for Prof. Benjamin Hughes, international commercial arbitration attorney\rand arbitrator\r\rHague Conference on Private International Law, Legal Intern, International Commercial\rTransactions\r\rHills Governance Center, Yonsei, Executive Researcher\r\rPublications and Presentation\rSun Yi, Internationalization of healthcare business and data protection, presented on 31 October, 2019\r\rSun Yi, Class Arbitration in International Consumer Contract, JOURNAL OF ARBITRATION STUDIES, No. 26, March, 2017\rSun Yi, Treaty Report: Joint Statement for Tripartite Partnership Among Republic of Korea, Japan And People’s\rRepublic Of China, 2 JOURNAL OF EAST ASIA AND INTERNATIONAL LAW, No. 2 (2009)\rSun Yi, Transparency International Country corruption Report Korea, Korean version (translation into Korean),\rTransparency International (2006)\rSun Yi, Mini-Column, CHOSUN DAILY, February 2000\r\rAwards and Honors\r2020 ~ 2021\r\rDirector of Legal Research group for the private international law\r\r2015\r\rYoung Korean Lawyer’s Award, endorsed by Ministry of Justice and International Association\rof Korean Lawyers\r\r2015 ~ 2016\r2014\r2009\r\rSeegmiller Scholarship (full-time academic merit scholarship)\r\rFull sponsorship by Korean Bar associate for International Bar Association Annual\rConference in Tokyo\r\rHague Academy of international law full scholarship for Private International Law Courses\r\r105"
  },
  {
    "id": "page-13c4-9253",
    "text": "Tae-kyu Lee CEO\r\rScale Up Partners Ltd, KOREA\r\rBachelor of Science in Electronic Engineering, Korea University College of Engineering\rMaster of Pharmaceutical Industry, Sungkyunkwan University College of Pharmacy\r2020 ~\r\rCEO of Scale-Up Partners\r\r2007 ~ 2020.2\r\rWonik Investment Partners Co., Ltd\r\r1999 ~ 2006\r\r1990 ~ 1999\r\rIT Convergence/Bio Venture Investment, Incubation, and IPO Consulting\rHead of Investment Division of Venture Investment Headquarters\r\rIT Convergence/Bio Venture Investment, Incubation, and IPO Consulting\rKorea Ventures Co., Ltd.,(Director)\r\rInvestment examiner at Venture Investment Headquarters\r\rIT Convergence Venture Investment, Incubation, and IPO Consulting\rSamsung Electronics Co., Ltd. Technical Planning Team,\r\rTechnology planning and mid- to long-term business planning in the IT field\r\rKenneth Walsh Ph.D.\r\rUniversity of Virginia, USA\r\r1984\r\rPhD\r\r2020\r\rDistinguished Researcher Award, University of Virginia\r\r2018 ~\r\rUniversity of Virginia - School of Medicine; Lockhart B. McGuire Professor of Internal\r\r1978\r\r2020 ~\r\r2011\r\r2009 ~ 2015\r2008 ~ 2018\r2008 ~ 2018\r2004 ~2016\r2001 ~2018\r2000 ~2001\r\r1993 ~ 2001\r\rBS\r\rUniversity of California, Berkeley\r\rBowling Green State University\r\rProfessor, Department of Biochemistry and Molecular Genetics (UVA)\r\rMedicine; Director of the Hematovascular Biology Center (HBC); Member, Robert M. Berne\rCardiovascular Research Center, Associate Member, Cancer Center\rDistinguished Investigator of the American Heart Association.\r\rCharter Member, CCHF Study Section, National Institutes of Health.\r\rAram V. Chobanian Distinguished Professor of Cardiovascular Medicine, Boston University\rSchool of Medicine.\r\rDirector, Whitaker Cardiovascular Institute, Boston University School of Medicine.\rAssociate Editor, Circulation.\r\rHead, Molecular Cardiology, Whitaker Cardiovascular Institute, Boston University School of\rMed icine. Professor of Medicine, Boston University School of Medicine.\rProfessor of Medicine, Tufts University School of Medicine.\r\rProgram Director, Division of Cardiovascular Research, St Elizabeth’s Medical Center,\r\rAssociate Professor, Department of Medicine; Department of Anatomy and Cell Biology;\r\rDepartment of Physiology; Graduate Program in Cell, Molecular and Developmental Biology;\rTufts University SOM.\r106"
  },
  {
    "id": "page-3abd-3acd",
    "text": "1993\r\rIrvine F. Page Young Investigator Award, AHA Council on Arteriosclerosis.\r\r1989 ~ 1993\r\rAssistant Professor, Department of Physiology and Biophysics, Case Western Reserve\r\r1990 ~ 1995\r\r1985 ~ 1988\r1979 ~ 1985\r\rEstablished Investigator of the American Heart Association.\rUniversity.\r\rPostdoctoral Fellow, Department of Biology, Massachusetts Institute of Technology. Advisor:\rP Schimmel.\r\rGraduate Student, Department of Biochemistry, University of California, Berkeley. Advisor: DE\rKoshland.\r\r1. N. W. Chavkin, G. Genet, M. Poulet, E. D. Jeffery, C. Marziano, N. Genet, H. Vasavada, E. A. Nelson, B.\r\rR. Acharya, A. Kour, J. Aragon, S. P. McDonnell, M. Huba, G. M. Sheynkman, K. Walsh, K. K. Hirschi (2022).\rEndothelial cell cycle state determines propensity for arterial-venous fate. Nature Commun. 13:5891.\rPMCID: PMC9537338.\r\r2. K.-D. Min, A. H. Polizio, A. Kour, M. C. Thel, K. Walsh (2022). Experimental ASXL1-mediated clonal\rhematopoiesis accelerates heart failure. J. Am. Heart Assoc. 11:e026154. PMCID: In process by journal.\r\r3. Y. Yoshida, I. Shimizu, A. Shimada, K. Nakahara, S. Yanagisawa, M. Kubo, S. Fukuda, C. Ishii, H. Yamamoto,\rT. Ishikawa, K. Kano, J. Aoki, G. Katsuumi, M. Suda, K. Ozaki, Y. Yoshida, S. Okuda, S. Ohta, S. Okamoto,\r\rY. Mi- nokoshi, K. Oda, T. Sasaoka, M. Abe, K. Sakimura, Y. Kubota, N. Yoshimura, S. Kajimura, M. Zuriaga,\rK. Walsh, T. Soga, T. Minamino (2022). Brown adipose tissue dysfunction promotes heart failure via a\rtrimethylamine N-ox- ide-dependent mechanism. Sci. Rep. 12:14883. PMCID: PMC9436957.\r\r4. M. A. Evans and K. Walsh (2022). Clonal hematopoiesis, somatic mosaicism, and age-associated disease.\rPhysiol. Rev. Online ahead of print Sep. 1. PMCID: In process by journal.\r\r5. A. Brojakowska, A. Kour, M. C. Thel, E. Park, M. Bisserier, V. N. S. Garikipati, L. Hadri, P. J. Mills, K. Walsh, D.\r\rA. Goukassian (2022). Retrospective analysis of somatic mutations and clonal hematopoiesis in astronauts.\rCommun. Biol. 5:828. PMCID: PMC9385668.\r\r6. S. Sano, K. Horitani, H. Ogawa, J. Halvardson, N. W. Chavkin, Y. Wang, M. Sano, J. Mattisson, A. Hata, M.\r\rDanielsson, E. Miura-Yura, A. Zaghlool, M. A. Evans, T. Fall, H. N. De Hoyos, J. Sundstrom, Y. Yura, A. Kour,\r\rY. Arai, M. C. Thel, Y. Arai, J. C. Mychaleckyj, K. K. Hirschi, L. A. Forsberg, K. Walsh (2022). Hematopoietic\rloss of Y chromosome leads to cardiac fibrosis and heart failure mortality. Science. 377:292-297. PMCID:\rNIHMSID1830716. Perspective in Science, Commentary in Science.\r\r7. K. Walsh, N. Raghavachari, C. Kerr, A. G. Bick, S. R. Cummings, T. Druley, C. E. Dunbar, G. Genovese, M. A.\r\rGoodell, S. Jaiswal, J. Maciejewski, P. Natarajan, A. V. Shindyapina, A. R. Shuldiner, E. B. Van Den Akker, J.\rVijg (2022). Clonal hematopoiesis analyses in clinical, epidemiologic, and genetic aging studies to unravel\runderlying mechanisms of age-related dysfunction in humans. Front Aging. 3:841796. PMCID: PMC9261374\r8. Y. Hayashi, I. Shimizu, Y. Yoshida, R. Ikegami, M. Suda, G. Katsuumi, S. Fujiki, K. Ozaki, M. Abe, K. Sakimura,\r\rS. Okuda, T. Hayano, K. Nakamura, K. Walsh, N. Z. Jespersen, S. Nielsen, C. Scheele, T. Minamino (2022).\r\rCoag- ulation factors promote brown adipose tissue dysfunction and abnormal systemic metabolism in\robesity. iScience. 25:104547. Comment in Nature. PMCID: PMC9218513.\r\r9. Y. Yura, J. D. Cochran, K. Walsh (2022). Therapy-related clonal hematopoiesis: A new link between cancer\rand cardiovascular disease. Heart Fail. Clin. 18:349-359. PMCID: PMC9219036.\r\r10. D. Goukassian, A. Arakelyan, A. Brojakowska, M. Bisserier, S. Hakobyan, L. Hadri, A.K. Rai, A. Evans,\r\rA. Se- bastian, M. Truongcao, C. Gonzalez, A. Bajpai, Z. Cheng, P.K. Dubey, S. Addya, P. Mills, K. Walsh,\rR. Kishore, M. Coleman, V.N.S. Garikipati (2022). Space flight associated changes in astronauts’ plasmaderived small extracellular vesicle microRNA: Biomarker identification. Clin. Transl. Med. 12:e845. PMCID:\rPMC9162436.\r\r11. Y. Wang, S. Sano, H. Ogawa, K. Horitani, M. A. Evans, Y. Yura, E. Miura-Yura, H. Doviak, K. Walsh (2022).\r\rMu- rine models of clonal haematopoiesis to assess mechanisms of cardiovascular disease. Cardiovasc.\rRes. 118:1413- 1432. PMCID: PMC9075001\r\r107"
  },
  {
    "id": "page-8683-d536",
    "text": "12. K. Gabisonia, G. Burjanadze, F. Woitek, A. Keles, M. Seki, N. Gorgodze, L. Carlucci, S. Ilchenko, C. Kurishima,\rK. Walsh, H. Piontkivska, F. A. Recchia, T. Kasumov (2022). Proteome dynamics and bioinformatics reveal\r\rmajor al- terations in the turnover rate of functionally related cardiac and plasma proteins in a dog model\rof congestive heart failure. J. Cardiac Fail. 28:588-600. PMCID: Not applicable.\r\r13. K. Walsh, N. Raghavachari, C. Kerr, A. G. Bick, S. R. Cummings, T. Druley, C. E. Dunbar, G. Genovese,\rM. A. Goodell, S. Jaiswal, J. Maciejewski, P. Natarajan, A. V. Shindyapina, A. R. Shuldiner, E. B. Van Den\r\rAkker, J. Vijg (2022). Clonal hematopoiesis analyses in clinical, epidemiologic, and genetic aging studies\rto unravel underlying mechanisms of age-related dysfunction in humans. Front. Aging. 3:841796. PMCID:\rPMC9261374.\r\r14. Y. Yura, K. Walsh (2022). Therapy-related clonal hematopoiesis: A new link between cancer and\rcardiovascular disease. Shinzo. 54:268-278. PMCID: PMC9219036.\r\r15. M. Bisserier, N. Saffran, A. Brojakowska, A. Sebastian, A. C. Evans, M. Coleman, K. Walsh, P. J. Mills, V. N.\r\rS. Garikipati, A. Arakelyan, L. Hadri, D. A. Goukassian (2022). Emerging role of exosomal long non-coding\rRNAs in spaceflight-associated risks in astronauts. Front. Genet. 12:812188. PMCID: PMC8803151.\r\r16. N. W. Chavkin, S. Sano, Y. Wang, K. Oshima, H. Ogawa, K. Horitani, M. Sano, S. MacLauchlan, A. Nelson,\rK. Setia, T. Vippa, Y. Watanabe, J.J. Saucerman, K.K. Hirschi, N. Gokce, K. Walsh (2021). The cell surface\r\rreceptors Ror1/2 control cardiac myofibroblast differentiation. J. Am. Heart Assoc. 10:e019904. PMCID:\rPMC8403294.\r\r17. V. Gladyshev, S. Kritchevsky, S. Clarke, A. M. Cuervo, O. Fiehn, J. P. de Magalhaes, T. Mau, M. Maes, R.\r\rMoritz, L. Niedernhofer, E. Van Schaftingen, G. Tranah, K. Walsh, Y. Yura, B. Zhang (2021). Molecular damage\rin aging. Nature Aging. 1:1096-1106. PMCID: In process by journal.\r\r18. N. W. Chavkin, S. Cain, K. Walsh, K. K. Hirschi (2021). Isolation of murine retinal endothelial cells for\rnext-gen- eration sequencing. J. Vis. Exp.(176). Doi: 10.3791/63133. PMCID: PMC8641104.\r\r19. M. Bisserier, S. Shanmughapriya, A. K. Rai, C. Gonzalez, A. Brojakowska, V. N. S. Garikipati, M. Madesh,\rP. J. Mills, K. Walsh, A. Arakelyan, R. Kishore, L. Hadri, D. A. Goukassian (2021). Cell-Free mitochondrial DNA\ras a poten- tial biomarker for astronauts’ health. J. Am. Heart Assoc. 10:e022055. PMCID: PMC8751818.\r\r20. S. Sano, K. Walsh (2021). Hematopoietic JAK2V617F-mediated clonal hematopoiesis: AIM2 understand\rmecha- nisms of atherogenesis. J. Cardiovasc. Aging. 1:5. PMCID: PMC8360421.\r\r21. H. Ogawa, S. Sano, K. Walsh (2021). Employing the CRISPR-Cas system for clonal hematopoiesis\rresearch. Int. J. Phys. Med. Rehabil. 9:582. PMCID: PMC8360470.\r\r22. Y. Yura, E. Miura-Yura, Y. Katanasaka, K-D. Min, N. W. Chavkin, A. H. Polizio, H. Ogawa, K. Horitani, H.\r\rDovi- ak, M. A. Evans, M. Sano, Y. Wang, K. Boroviak, G. Philippos, A. Filipa Domingues, G. Vassiliou, S.\rSano, K. Walsh (2021). The cancer therapy-related clonal hematopoiesis driver gene Ppm1d promotes\rinflammation and non-is- chemic heart failure in mice. Circ. Res. 129:684-698. PMCID: PMC8409899.\r\r23. S. Sano, Y. Wang, H. Ogawa, K. Horitani, M. Sano, A. H. Polizio, A. Kour, Y. Yura, H. Doviak, K. Walsh\r\r(2021). TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced\rcardiomyopathy by aug- menting a neutrophil-mediated cytotoxic response. JCI Insight. 6(13):e146076.\rPMCID: PMC8410064.\r\r24. E. Park, M. A. Evans, H. Doviak, K. Horitani, H. Ogawa, Y. Yura, Y. Wang, S. Sano, K. Walsh (2021).\rBone marrow transplantation procedures in mice to study clonal hematopoiesis. J. Vis. Exp. (171). doi:\r10.3791/61875. PMCID: PMC8439117.\r\r25. N. W. Chavkin, K.-D. Min, K. Walsh. Importance of clonal hematopoiesis in heart failure. Trends\r\rCardiovasc. Med. 2021 Apr 20:S1050-1738(21)00049-9. doi: 10.1016/j.tcm.2021.04.005. Online ahead of\rprint. PMCID: PMC8526615.\r\r26. C. Mazzotta, S. Basu, A. Gower, S. Karki, M. Farb, E. Sroczynski, E. Zizza, A. Sarhan, A. Pande, K. Walsh,\r\rN. Do- brilovic, N. Gokce (2021). Perivascular adipose tissue inflammation in ischemic heart disease.\rArterioscler. Thromb. Vasc. Biol. 41:1239-1250. PMCID: PMC7904602.\r\r27. K.-D. Min, A. Kour, K. Walsh (2021). The role of clonal haematopoiesis in cardiovascular diseases:\repidemiology and experimental studies. J. Intern. Med. 228:507-517. PMCID: PMC8375669.\r\r28. M. A. Evans, K. Walsh (2021). A single cell analysis of DNMT3A-mediated clonal hematopoiesis in heart\rfailure. Circ. Res. 128:229-231. PMCID: PMC7839253.\r108"
  },
  {
    "id": "page-18a7-51ae",
    "text": "29. M. A. Evans, S. Sano, K. Walsh (2021). Clonal haematopoiesis and cardiovascular disease: How low can\ryou go? Eur. Heart J. 42:266-268. PMCID: NIHMS1733614.\r\r30. J. J. Fuster, M. A. Zuriaga, V. Zorita, S. MacLauchlan, M. N. Polackal, V. Viana-Huete, A. Ferrer-Perez, N.\r\rMate- sanz, A. Herrero-Cervera, S. Sano, M. A. Cooper, H. Gonzalez-Navarro, K. Walsh (2020). TET2 loss of\r\rfunction-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity.\rCell Rep. 33:108326. PMCID: PMC7856871.\r\r31. N. W. Chavkin, K. Walsh, K. K. Hirschi (2020). Isolation of highly purified and viable retinal endothelial\rcells. J. Vasc. Res. 6:1-9. PMCID: PMC7850292.\r\r32. S. A. Shah, S. X. Cui, C. D. Waters, S. Sano, Y. Wang, H. Doviak, J. Leor, K. Walsh, B. A. French, F. H.\r\rEpstein (2020). Nitroxide-enhanced MRI of cardiovascular oxidative stress. NMR Biomed. 33:e4359. PMCID:\rPMC7904044. 27.\r\r33. Y. Wang, S. Sano, Y. Yura, Z. Ke, M. Sano, K. Oshima, H. Ogawa, K. Horitani, K.-D. Min, E. Miura-Yura, A.\r\rKour, M. A. Evans, M. A. Zuriaga, K. K. Hirschi, J. J. Fuster, E. M. Pietras, K. Walsh (2020). Tet2-mediated\r\rclonal hemato- poiesis in non-conditioned mice accelerates age-associated cardiac dysfunction. JCI\rInsight. 5:e135204. PMCID: PMC7213793.\r\r34. Y. Yura, S. Sano, K. Walsh (2020). Clonal hematopoiesis: A new step linking inflammation to heart failure.\rJACC Basic Transl. Sci. 5:196-207. PMCID: PMC7046537.\r\r35. C. Jung, M. A. Evans, K. Walsh (2020). Genetics of age-related clonal hematopoiesis and atherosclerotic\rcardio- vascular disease. Curr. Opin. Cardiol. 35:219-225. PMCID: PMC7138732.\r\r36. M. A. Evans, S. Sano, K. Walsh (2019). Cardiovascular disease, aging and clonal hematopoiesis. Annu.\rRev. Pathol. Mech. Dis. 15:419-438. PMCID: PMC7104598.\r\r37. S. Sano, Y. Wang, K. Walsh (2019). Somatic mosaicism: Implications for the cardiovascular system. Eur.\rHeart J. 41:2904-2907. PMCID: PMC7421771.\r\r38. S. Sano, Y. Wang, Y. Yura, M. Sano, K. Oshima, Y. Yang, Y. Katanasaka, K.-D. Min, S. Matsuura, K. Ravid,\r\rG. Mohi, K. Walsh (2019). JAK2V617F-mediated clonal hematopoiesis accelerates pathological remodeling\rin murine heart failure. JACC Basic Transl. Sci. 4:684-697. PMCID: PMC6834960. Accompanied by editorial.\r\r39. S. Sano, Y. Wang, M. A. Evans, Y. Yura, M. Sano, H. Ogawa, K. Horitani, H. Doviak, K. Walsh (2019).\r\rLentiviral CRISPR/Cas9-mediated genome editing for the study of hematopoietic cells in disease models.\rJ. Vis. Exp. (152), e59977. PMCID:PMC7249700.\r\r40. Y. Wang, S. Sano, K. Oshima, M. Sano, Y. Watanabe, Y. Katanasaka, Y. Yura, C. Jung, A. Anzai, F. K. Swirski,\r\rN. Gokce, K. Walsh (2019). Wnt5a-mediated neutrophil recruitment has an obligatory role in pressure\roverload-in- duced cardiac dysfunction. Circulation. 140:487-499. PMCID: PMC6684855.\r\r41. R. Kivela, K. Amudhala Hemanthakumar, K. Vaparanta, M. Robciuc, Y. Izumiya, H. Kidoya, N. Takakura,\rX. Peng, D. B. Sawyer, K. Elenius, K. Walsh, K. Alitalo (2019). Endothelial cells regulate physiological\r\rcardiomyocyte growth via VEGFR2 -mediated paracrine signaling. Circulation 139:2570-2584. PMCID:\rPMC6553980.\r\r42. A. Anzai, J. Mindur, L. Halle, S. Sano, J. Choi, S. He, C. McAlpione, C. Chan, F. Kahles, C. Valet, A. Fenn, M.\r\rNairz, S. Rattik, Y. Iwamoto, D. Fairweather, K. Walsh, P. Libby, M. Nahrendorf, F. Swirski (2019). Self-reactive\r\rCD4+ IL-3+ T cells amplify autoimmune inflammation in myocarditis by inciting monocyte chemotaxis. J.\rExp. Med. 216:369-383. PMCID: PMC6363430.\r\r43. S. Sano, Y. Wang, K. Walsh (2018). Clonal hematopoiesis and its impact on cardiovascular disease. Circ.\rJ. 83:2- 11. PMCID: PMC6310086.\r\r44. S. Maruyama, C.-L. Wu, S. Yoshida, D. Zhang, P.-H. Li, F. Wu, J. Parker Duffen, R. Yao, B. Jardin, I. M.\r\rAdham, R. Law, J. Berger, R. Di Marchi, K. Walsh (2018). Relaxin family member Insulin-like Peptide 6\rameliorates cardiac fibrosis and prevents cardiac remodeling in murine heart failure models. J. Am. Heart\rAssoc. 7: pii: e008441. doi: 10.1161/JAHA.117.008441. PMCID: PMC6220528.\r\r45. S. Sano, K. Oshima, Y. Wang, Y. Katanasaka, M. Sano, K. Walsh (2018). CRISPR-mediated gene editing\r\rto assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ. Res.\r123:335-341. PMCID: PMC6054544. Accompanied by Editorial and selected for Journal Cover.\r\r109"
  },
  {
    "id": "page-7c27-95ac",
    "text": "46. S. Sano, K. Oshima, Y. Wang, S. MacLauchlan, Y. Katanasaka, M. Sano, M. A. Zuriaga, M. Yoshiyama, D.\rGoukassian, M. A. Cooper, J. J. Fuster, K. Walsh (2018). Tet2-mediated clonal hematopoiesis accelerates\r\rheart failure through a mechanism involving the IL-1γ/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71:875-\r\r886. PMCID: PMC5828038. Accompanied by Editorial and Research highlight in Nature Reviews, Cardiology;\rEditor’s Choice in Science, Translational Medicine.\r\r47. J. J. Fuster, K. Walsh (2018). Somatic mutations and clonal hematopoiesis: unexpected potential new\rdrivers of age-related cardiovascular disease. Circ. Res. 122:523-532. PMCID: PMC5826570.\r\r48. M. Seki, J. C. Powers, S. Maruyama, M. A. Zuriaga, C.-L. Wu, C. Kurishima, L. Kim, J. Johnson, A.\r\rPoidomani, T. Wang, E. Munoz, S. Rajan, J. Y. Park, K. Walsh, F. A. Recchia (2018). Acute and chronic\r\rincreases of circulating FSTL1 normalize energy substrate metabolism in pacing-induced heart failure.\rCirc. Heart Fail. 11:e004486. PMCID: PMC5765881.\r\r49. M. A. Zuriaga, J. J. Fuster, M. G. Farb, S. MacLauchlan, R. Breton-Romero, S. Karki, D. T. Hess, C. M. Apovian,\rN. M. Hamburg, N. Gokce, K. Walsh (2017). Activation of non-canonical WNT signaling in human visceral\radipose tissue contributes to local and systemic inflammation. Sci. Rep. 7:17326. PMCID: PMC5725530.\r\r50. R. L. Neppl, C.-L. Wu, K. Walsh (2017). IncRNA Chronos is an aging-induced inhibitor of muscle\rhypertrophy. J. Cell Biol. 216:3497-3507. PMCID: PMC5674882.\r\r51. S. MacLauchlan, M. A. Zuriaga, J. J. Fuster, C. Cuda, J. Jonason, F. Behzadi, J. Parker Duffen, G. K. Haines\r\rIII, T. Aprahamian, H. Perlman (2017). Genetic deficiency of Wnt5a diminishes disease severity in a murine\rmodel of rheumatoid arthritis. Arthr. Res. Ther. 19:166. PMCID: PMC5518154.\r\r52. S. P. Sasi, X. Yan, M. Zuriaga-Herrero, H. Gee, J. Lee, R. Mehrzad, J. Song, J. Onufrak, J. Morgan, H.\r\rEnderling, K. Walsh, R. Kishore, D. A. Goukassian (2017). Different sequences of fractionated low-dose\rproton and single iron-radiation-induced divergent biological responses in the heart. Radiat. Res. 188:191203. PMCID: Not applicable.\r\r53. M. A. Zuriaga, J. J. Fuster, N. Gokce, K. Walsh (2017). Humans and mice display opposing patterns\rof “brown- ing” gene expression in visceral and subcutaneous white adipose tissue depots. Frontiers\rCardiovasc. Med. 4:27. PMCID: PMC5418233.\r\r54. K. K. Hirschi, S. Nicoli, K. Walsh (2017). Hematopoiesis lineage tree uprooted: Every HSPC is a rainbow.\rDev. Cell. 41:7-9. Review. PMCID: Not applicable.\r\r55. S. Karki, D. Ngo, M. Farb, S.-Y. Park, S. Saggese, N. Hamburg, D. Hess, B. Carmine, K. Walsh, N. Gokce\r\r(2017). WNT5A regulates adipose tissue angiogenesis via anti-angiogenic VEGFA165b in obese humans.\rAm. J. Phys. Heart. 313:H200-H206. PMCID: PMC6148084.\r\r56. C.-L. Wu, Y. Satomi, K. Walsh (2017). RNA-seq and metabolomic analyses of Akt1-mediated muscle\rgrowth reveals regulation of regenerative pathways and changes in the muscle secretome. BMC Genomics\r18:181-199. PMCID: PMC5314613.\r\r57. J. J. Fuster, S. MacLauchlan, M. A. Zuriaga, M. N. Polackal, A. C. Ostriker, R. Chakraborty, C.-L. Wu,\r\rS. Sano, S. Muralidharan, C. Rius, J. Vuong, S. Jacob, V. Muralidhar, A. A. B. Robertson, M. A. Cooper, V.\rAndres, K. K. Hirschi, K. A. Martin, K. Walsh (2017). Clonal hematopoiesis associated with Tet2 deficiency\raccelerates atherosclerosis de- velopment. Science 355:842-847. PMCID: PMC5542057. Accompanied by\r\rPerspective in Science, News and Views in Nature; Research Highlights in Nature, Nature Immunology and\rNature Reviews Drug Discovery. Editor’s choice, Science Signaling.\r\r110"
  },
  {
    "id": "page-86cc-840d",
    "text": "Toshio Suda M.D., Ph.D.\r\rKumamoto University, JAPAN\r\r1974\r\rGraduated from Yokohama City University School of Medicine\r\r2015 ~ present\r\rProfessor, Cancer Science Institute of Singapore, National University of Singapore\r\r2015 ~ present\r\rDirector and Distinguished Professor, International Research Center for Medical Sciences,\rKumamoto University\r\r1. Yang C, Yokomori R, Chua LH, Tan SH, Sanda T, Suda T; Mitochondria transfer restores stress erythropoiesis\rby altering the bioenergetic profiles of a subpopulation of early erythroblasts marked by CD47. J Exp Med,\rin press\r\r2. Yokomizo T, Ideue, T, Sato T, Takeda N, Kurokawa M, Komatsu N, Araki, K, Osato M, Suda T: Tracing the\rorigin of hierarchical hematopoietic structure in fetal liver. Nature 609:779-784,2022\r\r3. Umemoto T, Johansson A, Ahmad SAI, Hashimoto M, Kubota S, Odaka H, Kataoka M, Era T, Sashida G,\r\rSuda T: The suppression of reductive glutamine metabolism is required to preserve stem cell features in\r\rprimed hematopoietic stem cells. EMBO J. 2022 Apr 19;41(8):e109463. doi: 10.15252/embj.2021109463.\rEpub 2022 Mar 1.PMID: 35229328\r\r4. Nakamura-Ishizu A, Ito K, Suda T: Hematopoietic stem cell metabolism during development and aging.\rDev. Cell. 54: 239-255, 2020\r\r5. Umemoto T, Hashimoto M, Matsumura T, Nakamura-Ishizu A, Suda T. Ca2+-mitochondria axis drives cell\r\rdivision in hematopoietic stem cells. J Exp Med. 2018 Jun 26. pii: jem.20180421. doi:10.1084/jem.20180421\r\r111"
  },
  {
    "id": "page-cf9c-2cff",
    "text": ""
  },
  {
    "id": "page-546f-4b95",
    "text": ""
  },
  {
    "id": "page-b437-2b1f",
    "text": "114"
  },
  {
    "id": "page-c786-66b2",
    "text": "115"
  },
  {
    "id": "page-2f94-915c",
    "text": "대한민국 미래의학의 발전을 바라는 여러분 모두가 후원자가 되어 주세요.\r\r재단은 미래의학생명과학 분야의 사회일반의 이익을 목적으로 설립된 과학기술정보통신부 산하 비영리법인이며 기획재정부\r장관이 지정기부금단체로 지정·고시한 공익법인입니다(지정기간 : 2022.02.02 ~ 2027.12.31).\r\r재단은 소외되기 쉬운 차세대 유망 연구자와 산업분야를 꾸준히 지원합니다. 민간 비영리법인인 재단이 주도하는 산·학·연\r\r오픈이노베이션 플랫폼(UTO, Universal Tech Organizer. 특허 제 10-2228853 호, 제 10-2354270 호, 특허-2022-0118011)\r을 기반으로 우수 기술을 조기에 발굴하여 기술 사업화를 촉진하고 바이오 스타트업 맞춤형 액셀러레이팅 프로그램을 제공합니\r다.\r\r이를 통해 재단은 기업의 지속 성장의 효율성을 극대화하고 자본시장으로 이어주는 연결고리로써 꾸준히 지원하여 원천기술\r보유자인 과학자들이 보다 안심하고 기술 실용화에 도전할 수 있는 장이 될 것입니다. 더불어 재단의 후원금을 창업기업에 직접\r\r투자하여 건전한 엔젤 투자 모형을 구축에 기여하고 지속적인 유관산업 분야와 연구자 매칭을 통한 후행투자(Follow-on Inves\rtment) 기회를 제공하여 대한민국 미래성장동력 발굴에 기여할 것입니다.\r\r미래의학생명과학 분야의 발전을 위해 여러분의 연대가 우리의 희망입니다. 우리는미래의학연구재단입니다.\r\r1 재단법인 미래의학연구재단의 기부자 명부에 올리겠습니다.\r\r2 우리 재단은 지정기부금단체입니다. 지정기부금 공제 혜택을 받으실 수 있습니다.\r3 지정기부금 세액공제를 위한 기부금 영수증을 우송해 드립니다.\r\r4 2022년 기부금 세액공제율이 5% 일시 상향되어 연말정산시 세금감면 혜택이 확대됩니다.(소득법제59조의4항)\r\r116"
  },
  {
    "id": "page-6ee1-5252",
    "text": "117"
  },
  {
    "id": "page-1566-15cc",
    "text": "118"
  },
  {
    "id": "page-a9dd-75c5",
    "text": "119"
  },
  {
    "id": "page-497f-c6fd",
    "text": "120"
  },
  {
    "id": "page-8fca-8b7f",
    "text": "121"
  },
  {
    "id": "page-b30e-ec91",
    "text": "122"
  },
  {
    "id": "page-9b54-4ec2",
    "text": "123"
  },
  {
    "id": "page-2160-077f",
    "text": ""
  },
  {
    "id": "page-a6b0-2365",
    "text": ""
  },
  {
    "id": "page-0b64-c0f1",
    "text": "13\r\r9 772671 915006\r\rISSN 2671-9150"
  }
]